Table of Contents Author Guidelines Submit a Manuscript
Disease Markers
Volume 27 (2009), Issue 6, Pages 311-316

Soluble CD26 Levels and Its Association to Epidemiologic Parameters in a Sample Population

Loretta De Chiara,1 Ana M. Rodríguez-Piñeiro,1 Oscar J. Cordero,2 Francisco J. Rodríguez-Berrocal,1 Daniel Ayude,1 Francisco J. Rivas-Hervada,3 and María Páez de la Cadena1

1Universidad de Vigo, Facultad de Biología, Departamento de Bioquímica, Genética e Inmunología, As Lagoas-Marcosende s/n, 36310 Vigo, Spain
2Universidad de Santiago de Compostela, Facultad de Biología, Departamento de Bioquímica y Biología Molecular, San Francisco s/n, Campus Universitario Norte, 15782 Santiago de Compostela, Spain
3Peugeot Citroën Automóviles España, S.A. Centro de Vigo, Servicio Médico, Av. Citroën 3 y 5, 36210 Vigo, Spain

Received 6 January 2010; Accepted 6 January 2010

Copyright © 2009 Hindawi Publishing Corporation. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Introduction: Previous studies have suggested the use of soluble CD26 (sCD26) as a tumour marker for the detection of colorectal cancer (CRC) and advanced adenomas. The aim of this study was to assess the sCD26 concentration in a large cohort to evaluate its association to epidemiologic parameters and CRC-related symptoms/pathologies.

Subjects and methods: Serum samples were collected from 2,754 putatively healthy individuals with ages ranging from 30–65 years, and with personal or familial history of polyps, CRC and/or CR symptoms. sCD26 levels were measured by ELISA.

Results: No association was found between the sCD26 concentration and age (< 50 and ≥ 50), the personal or familial history of polyps or CRC, rectal bleeding, haemorrhoids or diverticula. However, sCD26 was related to non-inflammatory benign pathologies (excluding rectal bleeding, changes in bowel habits, haemorrhoids, diverticula) and to inflammatory benign pathologies.

Discussion: Our results confirm that the sCD26 can be easily offered and evaluated in a large cohort. Additionally, the validation of sCD26 as a tumour marker for screening and case-finding purposes requires a further comparison with an established non-invasive test like the faecal occult blood.